AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
333.96B
Market cap333.96B
Price-Earnings ratio
81.34
Price-Earnings ratio81.34
Dividend yield
3.34%
Dividend yield3.34%
Average volume
8.16M
Average volume8.16M
High today
$191.39
High today$191.39
Low today
$188.29
Low today$188.29
Open price
$191.39
Open price$191.39
Volume
3.71M
Volume3.71M
52 Week high
$218.66
52 Week high$218.66
52 Week low
$163.63
52 Week low$163.63

ABBV News

TipRanks 15h
AbbVie’s XEN63 Gel Stent Study: A New Hope for Glaucoma Treatment?

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

TipRanks 15h
AbbVie’s Pediatric Crohn’s Disease Study: A Potential Game-Changer?

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

TipRanks 3d
AbbVie Stock Jumps on $2.1B Capstan Therapeutics Deal

AbbVie (ABBV) stock rallied on Monday after the company announced its $2.1 billion agreement to acquire Capstan Therapeutics. It will use cash to fund this tran...

Analyst ratings

60%

of 30 ratings
Buy
60%
Hold
40%
Sell
0%

More ABBV News

Seeking Alpha 4d
AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash

AbbVie (NYSE:ABBV) has agreed to acquire clinical-stage biotechnology company Capstan Therapeutics for up to $2.1 billion in cash. The transaction is subject t...

AbbVie to acquire Capstan Therapeutics for up to $2.1B in cash

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.